Sunshine Biopharma (SBFM)

$1.47 +0.06 (4.26%)
Market Cap 6.79M
Revenue (ttm) 34.87M
Net Income (ttm) -5.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14.71%
Debt to Equity Ratio 0.00
Volume 44,600
Avg Vol 373,034
Day's Range N/A - N/A
Shares Out 4.56M
Stochastic %K 3%
Beta 1.41
Analysts Strong Sell
Price Target $7.00

Company Profile

Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pa...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: (954) 330-0684
Address:
333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, United States
Pomacanthus
Pomacanthus Jun. 26 at 6:37 PM
$SBFM I feel pretty confident based soley on a hunch that cancer cure news will drop tomorrow. only question is how high will it go? Imma guess $3.25 🚀🚀🚀
0 · Reply
Masterrunner
Masterrunner Jun. 26 at 3:19 PM
$SBFM
0 · Reply
VMAESA
VMAESA Jun. 25 at 1:51 PM
$GCTK So ya tellin’ me people actually pay attention to news, catalysts to make money in stock market? Lmao😂 If you only knew🤦‍♂️ $CRCL $SBFM $ULY
0 · Reply
MxPw
MxPw Jun. 24 at 8:27 PM
$SBFM
0 · Reply
MxPw
MxPw Jun. 24 at 7:11 PM
$SBFM
0 · Reply
contra7
contra7 Jun. 24 at 5:42 PM
$SBFM Using the industry standards for revenue multiples, this company can justify a market cap of over $200 million right now. With over 70 generics available in Canada, several new additions with billion dollar global markets, and promising results in their oncology pipeline ….severely undervalued is an understatement for this company.
2 · Reply
MxPw
MxPw Jun. 24 at 4:27 PM
$SBFM
0 · Reply
Geo1313
Geo1313 Jun. 24 at 3:17 PM
$SBFM
1 · Reply
Geo1313
Geo1313 Jun. 24 at 3:13 PM
$SBFM 2 years ago,price per share(value)🚀🔥🧨🕛
0 · Reply
Newyork_
Newyork_ Jun. 24 at 4:06 AM
$SBFM been a long time since I check on my biggest L lmfao. I’m hella impressed company still going . 😂
0 · Reply
Latest News on SBFM
Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

Jun 11, 2025, 8:30 AM EDT - 15 days ago

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

May 15, 2025, 4:15 PM EDT - 6 weeks ago

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

May 6, 2025, 8:30 AM EDT - 7 weeks ago

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

Apr 21, 2025, 8:30 AM EDT - 2 months ago

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

Apr 3, 2025, 10:50 AM EDT - 3 months ago

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Apr 2, 2025, 1:20 PM EDT - 3 months ago

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Apr 2, 2025, 11:35 AM EDT - 3 months ago

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

Apr 2, 2025, 8:00 AM EDT - 3 months ago

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

Apr 1, 2025, 5:09 PM EDT - 3 months ago

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

Mar 24, 2025, 8:00 AM EDT - 3 months ago

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

Mar 10, 2025, 9:00 AM EDT - 3 months ago

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

Jan 21, 2025, 8:00 AM EST - 5 months ago

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Jan 15, 2025, 8:00 AM EST - 5 months ago

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

Dec 9, 2024, 7:30 AM EST - 7 months ago

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

Sunshine Biopharma Launches a New Generic Prescription Drug

Dec 4, 2024, 4:05 PM EST - 7 months ago

Sunshine Biopharma Launches a New Generic Prescription Drug

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Dec 2, 2024, 8:00 AM EST - 7 months ago

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

Nov 6, 2024, 8:00 AM EST - 8 months ago

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

Sunshine Biopharma Launches Two New Generic Prescription Drugs

Sep 26, 2024, 8:00 AM EDT - 9 months ago

Sunshine Biopharma Launches Two New Generic Prescription Drugs

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Sep 4, 2024, 8:00 AM EDT - 10 months ago

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada

Aug 26, 2024, 8:00 AM EDT - 10 months ago

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada

Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

Aug 19, 2024, 8:00 AM EDT - 11 months ago

Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

Sunshine Biopharma Announces Reverse Stock Split

Aug 6, 2024, 8:00 AM EDT - 11 months ago

Sunshine Biopharma Announces Reverse Stock Split

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

Apr 19, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

Feb 15, 2024, 9:15 AM EST - 1 year ago

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

Feb 13, 2024, 9:00 AM EST - 1 year ago

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

Sunshine Biopharma Moves Principal Office to New York City

Dec 4, 2023, 8:30 AM EST - 1 year ago

Sunshine Biopharma Moves Principal Office to New York City

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

Nov 13, 2023, 8:30 AM EST - 1 year ago

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

Sep 21, 2023, 9:05 PM EDT - 1 year ago

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

Aug 11, 2023, 8:30 AM EDT - 2 years ago

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

May 16, 2023, 2:15 PM EDT - 2 years ago

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

May 16, 2023, 9:58 AM EDT - 2 years ago

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

May 12, 2023, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

May 11, 2023, 9:00 AM EDT - 2 years ago

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

Apr 5, 2023, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

Feb 28, 2023, 7:30 AM EST - 2 years ago

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

Feb 10, 2023, 7:35 AM EST - 2 years ago

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

Sunshine Biopharma Announces Share Repurchase Program

Jan 19, 2023, 7:30 AM EST - 2 years ago

Sunshine Biopharma Announces Share Repurchase Program

Sunshine Biopharma's Annual Letter to Shareholders

Dec 20, 2022, 8:00 AM EST - 2 years ago

Sunshine Biopharma's Annual Letter to Shareholders

4 Stocks Meeting GuruFocus' Value Screens in December

Dec 5, 2022, 5:46 PM EST - 2 years ago

4 Stocks Meeting GuruFocus' Value Screens in December

RM CACC WFG

Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project

Nov 16, 2022, 8:00 AM EST - 2 years ago

Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project

Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue

Oct 20, 2022, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue

Sunshine Biopharma Files Its Second Quarter Report With the SEC

Aug 4, 2022, 8:00 AM EDT - 3 years ago

Sunshine Biopharma Files Its Second Quarter Report With the SEC

Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona

Jul 28, 2022, 8:10 AM EDT - 3 years ago

Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona

Sunshine Biopharma: An Opportunity Knocking?

May 9, 2022, 11:03 AM EDT - 3 years ago

Sunshine Biopharma: An Opportunity Knocking?

Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market

Apr 28, 2022, 4:50 PM EDT - 3 years ago

Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market

Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ: SBFM)

Apr 28, 2022, 9:20 AM EDT - 3 years ago

Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ: SBFM)

Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market

Apr 26, 2022, 12:41 AM EDT - 3 years ago

Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market

Why Sunshine Biopharma Stock Is Surging

Apr 25, 2022, 10:57 AM EDT - 3 years ago

Why Sunshine Biopharma Stock Is Surging

Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells

Apr 25, 2022, 8:00 AM EDT - 3 years ago

Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells

Pomacanthus
Pomacanthus Jun. 26 at 6:37 PM
$SBFM I feel pretty confident based soley on a hunch that cancer cure news will drop tomorrow. only question is how high will it go? Imma guess $3.25 🚀🚀🚀
0 · Reply
Masterrunner
Masterrunner Jun. 26 at 3:19 PM
$SBFM
0 · Reply
VMAESA
VMAESA Jun. 25 at 1:51 PM
$GCTK So ya tellin’ me people actually pay attention to news, catalysts to make money in stock market? Lmao😂 If you only knew🤦‍♂️ $CRCL $SBFM $ULY
0 · Reply
MxPw
MxPw Jun. 24 at 8:27 PM
$SBFM
0 · Reply
MxPw
MxPw Jun. 24 at 7:11 PM
$SBFM
0 · Reply
contra7
contra7 Jun. 24 at 5:42 PM
$SBFM Using the industry standards for revenue multiples, this company can justify a market cap of over $200 million right now. With over 70 generics available in Canada, several new additions with billion dollar global markets, and promising results in their oncology pipeline ….severely undervalued is an understatement for this company.
2 · Reply
MxPw
MxPw Jun. 24 at 4:27 PM
$SBFM
0 · Reply
Geo1313
Geo1313 Jun. 24 at 3:17 PM
$SBFM
1 · Reply
Geo1313
Geo1313 Jun. 24 at 3:13 PM
$SBFM 2 years ago,price per share(value)🚀🔥🧨🕛
0 · Reply
Newyork_
Newyork_ Jun. 24 at 4:06 AM
$SBFM been a long time since I check on my biggest L lmfao. I’m hella impressed company still going . 😂
0 · Reply
Hankies
Hankies Jun. 24 at 2:35 AM
$SBFM Barcoding for months. At least an offering should be off the table for a while. Dilution will crush this below a buck again. Nasdaq would delist for sure. I dont recall the Nasdaq warning, but they can't RS for like 2 years from that letter? Might average down next dip to 1.20 or so. So much potential, just shitty and shady mgmt.
0 · Reply
Masterrunner
Masterrunner Jun. 24 at 12:17 AM
$SBFM Well well well... look who’s still trash. Checking in on $SBFM, my worst financial decision since buying a timeshare in Aruba, where by I think Slilaty bought a mansion with our 💰. All that “exciting news,” and the stock still performs like it’s allergic to green candles. 📉 To the bulls still in here, you’re not failures, you’re just incredibly patient test subjects in a live experiment called “How low can it go?” Stay strong, delusion squad. 💎
0 · Reply
MxPw
MxPw Jun. 23 at 10:44 PM
$SBFM
0 · Reply
donemedirty
donemedirty Jun. 21 at 12:13 AM
$SBFM yahoo had it at 300 for a high ,I looked today and it show 7 what happen
1 · Reply
contra7
contra7 Jun. 20 at 5:14 PM
$SBFM Nothing but growth and a whole lot of good news here since last August which has definitely not been reflected in the SP. We are sitting on very solid support and this thing seems to be coiled and compressed for an imminent move up. The company is performing at an all time high as far as revenue and expansion are concerned while sitting very close to all time lows. Only way to go is up ⬆️ from here, the question is how high?
0 · Reply
Catracho5
Catracho5 Jun. 20 at 1:58 PM
$SBFM When delisting?
1 · Reply
MxPw
MxPw Jun. 20 at 1:12 PM
$SBFM
0 · Reply
Bat_shtt_crazy
Bat_shtt_crazy Jun. 20 at 1:08 PM
$SBFM So much for my big buy at 1.20 this morning
0 · Reply
Bat_shtt_crazy
Bat_shtt_crazy Jun. 20 at 11:06 AM
$SBFM FYI short idiots 300.00 PT. Lolls like I’m buying more today
0 · Reply
Jahubba
Jahubba Jun. 19 at 7:15 PM
$SBFM Does anyone know why Nasdaq has share amount at 2.7 million and stochwitts and my phone app has it at 4.7?
0 · Reply
FastMonte
FastMonte Jun. 19 at 1:46 AM
$SBFM I feel bad for the Nora people. They actually look like nice wholesome people. Much like the shareholders the leadership fkd. Do they know the parent company they work for is run by slimeball pieces o $#!+ I wouldn't piss on if they were fire?
1 · Reply
contra7
contra7 Jun. 19 at 12:39 AM
$SBFM So one share was sold under the bid at $1.30 at 7:59 which caused an 11% drop from $1.55 to $1.30 on Webull. RH closed at $1.49 tho 🤷🏾‍♂️
1 · Reply